Dear Members, You are invited to join Dr. Daniel Weiner for the 17th Advanced Level Workshop on Pharmacokinetic-Pharmacodynamic Data Analysis in Munich, Germany. Secure your place by registering early and receive a 20% discount! (expires 18 March 2015)
Interested in a custom on-site training course? Follow the link to view the benefits of on-site training and to request a proposal: http://info.certara.com/contact-us-for-custom-on-site-training 17th Advanced Level Workshop on Pharmacokinetic - Pharmacodynamic Data Analysis May 18-21, 2015 Munich, Germany Register Here: https://www.certara.com/training/classes/73 Learn to apply advanced approaches for conducting PK/PD analysis. This course aims to give the course participants confidence and encouragement to have a go at PK/PD and to practice PK/PD data analysis on real life case studies from discovery, preclinical and development. The program is comprised of lectures and group exercises with discussion, combined with hands-on PK/PD data analysis sessions. Who should attend? Scientists with at least five years of experience in PK/PD modeling. Qualified graduate students. Topics include: Dose-response-time analysis, advanced principles of turnover modeling including modeling tolerance and rebound, approaches to TMDD modeling, approaches to optimizing sampling collection times, modeling PD effects for combination drug treatments, pattern recognition, and translational aspects of PK/PD modeling. Course includes: Complimentary copy of Pharmacokinetic & Pharmacodynamic Data Analysis [with CDROM] by Johan Gabrielsson and Dan Weiner. Lectures, group exercises with discussion, and hands-on PK/PD data analysis including population PK/PD modeling using Phoenix WinNonlin and NLME. Discussions and exercises will enable participants to master state-of-the-art approaches to real-life problems. Daniel Weiner Ph.D. Dr. Weiner has extensive drug development experience and has served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence assessment. Prior to his previous tenure with Pharsight as a Senior Vice President, Dr. Weiner held several management positions including Head, Biostatistics, Merrell Dow Pharmaceuticals; Vice President, Statistical Consultants, Inc.; Vice President, Syntex Development Research; Senior Vice President and Principal Scientist, Quintiles, and most recently, Senior Vice President and Global Head of Clinical Development at IVAX Research. Kind regards, Andre Keller Certara(tm) 5520 Dillard Dr., Suite 260 Cary, NC 27518 Tel +1-919-852-4611 www.certara.com<http://www.certara.com/> NOTICE: The information contained in this electronic mail message is intended only for the personal and confidential use of the designated recipient(s) named above. This message may be an attorney-client communication, may be protected by the work product doctrine, and may be subject to a protective order. As such, this message is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this message in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and e-mail and destroy any and all copies of this message in your possession (whether hard copies or electronically stored copies). Thank you. buSp9xeMeKEbrUze
